Inspire Medical Systems' stock fell 5.03% during extended trading on Wednesday, as investors reacted negatively to the company's financial guidance for the coming year.

The medical technology firm reported strong fourth-quarter 2025 results, with revenue rising 12% year-over-year to $269.1 million, beating analyst expectations. However, the company's 2026 revenue outlook of $950 million to $1 billion fell short of the FactSet consensus estimate of $1.01 billion, representing a growth rate of just 4% to 10%.

While quarterly performance exceeded expectations, the market focused on the revised forward guidance, which signals potentially slower growth ahead. The company also provided adjusted EPS guidance of $1.85 to $2.35 for 2026, with investors weighing these projections against current valuation metrics.